Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Open Access
- 1 May 2021
- journal article
- research article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 29 (3) , 268-272
Abstract
Joon-Yong Bae, Gee Eun Lee, Heedo Park, Juyoung Cho, Jeonghun Kim, Jungmin Lee, Kisoon Kim, Jin Il Kim,* and Man-Seong Park,*. Biomolecules & Therapeutics 2021;29:268-72. https://doi.org/10.4062/biomolther.2021.032Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018M3A9H4056537)
- Ministry of Science and ICT, South Korea
This publication has 8 references indexed in Scilit:
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsNew England Journal of Medicine, 2021
- A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroPLOS Computational Biology, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- COVID-19: the worst may be yet to comeThe Lancet, 2020
- COVID-19, school closures, and child poverty: a social crisis in the makingThe Lancet Public Health, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysisScientific Reports, 2019
- Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza VirusesJournal of Virology, 2019